The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Ryan Zander; Weiguo Cui

doi:10.1080/21645515.2017.1345833

Back

The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Journal article

Open access

Peer reviewed

The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Ryan Zander and Weiguo Cui

Human vaccines & immunotherapeutics, Vol.13(10), pp.2269-2271

10/03/2017

DOI: 10.1080/21645515.2017.1345833

PMCID: PMC5647994

PMID: 28708956

Files and links (1)

url

https://doi.org/10.1080/21645515.2017.1345833View

Published (Version of record) Open Access

Abstract

Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.

Animals

Antigens, CD19 - immunology

Antigens, Neoplasm - immunology

Bacteria - immunology

Bacteria - pathogenicity

Cancer Vaccines - therapeutic use

Humans

Immunization, Secondary

Immunotherapy, Adoptive - adverse effects

Immunotherapy, Adoptive - methods

Mice

Neoplasms - therapy

Receptors, Antigen, T-Cell - immunology

Reproducibility of Results

T-Lymphocytes - immunology

Vaccination

Details

Title: Subtitle: The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors
Creators: Ryan Zander - University of Iowa, Microbiology and Immunology
Weiguo Cui - Medical College of Wisconsin
Resource Type: Journal article
Publication Details: Human vaccines & immunotherapeutics, Vol.13(10), pp.2269-2271
DOI: 10.1080/21645515.2017.1345833
PMID: 28708956
PMCID: PMC5647994
ISSN: 2164-5515
eISSN: 2164-554X
Grant note: R01 AI125741 / NIAID NIH HHS T32 HL007209 / NHLBI NIH HHS
Language: English
Date published: 10/03/2017
Academic Unit: Microbiology and Immunology
Record Identifier: 9984297324102771

Metrics

7 Record Views